About Biocon Our Business Research & Development Biocon's Technology Investors Media Careers CSR
  > INVESTORS
  Overview
  Corporate Structure
  Corporate Governance
  Company History
  Annual General Meeting
  Postal Ballot
  Investor FAQs
  Stock Info
  Financial Results
  Subsidiary Financials
  Annual Report
  Disclosure to Stock Exchange
  Nomination form
  Press Releases
  Presentations
  Analyst Coverage
  Investor Contacts
  
  
     
 
Disclosure to Stock Exchange


  June 2020
04 June Meetings conducted with Institutional Investors / Research Analysts. Download Pdf
02 June Meeting conducted with Institutional Investors / Research Analysts. Download Pdf
01 June Meeting conducted with Institutional Investors / Research Analysts Download Pdf
01 June Biocon's* Partner Mylan Receives Favourable Ruling from U.S. PTAB on Sanofi's Four Device Patents for Lantus® SoloSTAR® Download Pdf
  May 2020
29 May Meetings conducted with Institutional Investors / Research Analysts Download Pdf
27 May Meeting conducted with Institutional Investors / Research Analysts. Download Pdf
27 May Biocon Biologics Receives DCGI Approval for Emergency Use of CytoSorb® to Treat Critical COVID-19 Patients U.S. FDA recently approved CytoSorb for emergency use in COVID-19 patients Download Pdf
21 May Meetings conducted with Institutional Investors / Research Analysts. Download Pdf
20 May Meeting conducted with Institutional Investors / Research Analysts Download Pdf
19 May Meeting conducted with Institutional Investors / Research Analysts Download Pdf
19 May Biocon Biologics Receives EU GMP Certification for Multiple Biosimilars Manufacturing Facilities in Bengaluru; Expands its Manufacturing Capacity Includes Drug Substance and Drug Product Facilities for Pegfilgrastim, Trastuzumab, and Bevacizumab Download Pdf
14 May Biocon Earnings Q4FY20 Revenue Up 6% at Rs 1,644 Cr; EBITDA Down 11% at Rs 382 Cr; Net Profit Down 42% at Rs 123 Cr Download Pdf
14 May Outcome of the Board Meeting Download Pdf
14 May Appointment of Interim Chief Financial Officer (‘Interim CFO’) and Key Managerial Personnel of the Company Download Pdf
12 May Company Statement: Biocon Biologics Drug Substance Facilities in Bengaluru Receive EU GMP Certification Download Pdf
08 May Company Statement: Biocon's Receives EIR for Small Molecules API Manufacturing Facility for Pre -Approval and GMP U.S. FDA Inspection Download Pdf
  April 2020
28 Apr Biocon and Mylan Launch Fulphila®d, Biosimilar Pegfilgrastim, in Canada. Download Pdf
22 Apr Intimation for the Board Meeting and Trading Window Closure Download Pdf
20 Apr Meeting conducted with Institutional Investors/Research Analysts Download Pdf
16 Apr Company Statement : Biocon Biologics Receives EIR from U.S. FDA for Two Manufacturing Facilities, Inspection Stands Closed Download Pdf
14 Apr Biocon and Mylan Launch Fulphila®, Biosimilar Pegfilgrastim, in Australia Download Pdf
02 Apr Meeting conducted with Institutional Investors/Research Analysts. Download Pdf
01 Apr Biocon's Insulin Manufacturing Facility in Malaysia Receives EIR from U.S. FDA with Voluntary Action Indicated (VAI) Classification, Inspection Stands Closed Download Pdf
  March 2020
27 Mar Biocon & Biocon Biologics Ensuring Manufacturing of Life-Saving Medicines for Patients, Partners and Customers Download Pdf
20 Mar Company Statement: Biocon Receives EIR for Small Molecules API Manufacturing Facility for Post - Approval and GMP U.S. FDA Inspection Download Pdf
13 Mar Meetings conducted with Institutional Investors / Analysts. Download Pdf
11 Mar Biocon & Mylan Win Patent Litigation Asserted by Sanofi for Insulin Glargine Device Patent in U.S. Download Pdf
09 Mar Meeting conducted with Institutional Investors / Analysts. Download Pdf
09 Mar U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar Bevacizumab for Review Download Pdf
06 Mar Meeting conducted with Institutional Investors / Analysts. Download Pdf
  February 2020
27 Feb Biocon's Small Molecules API Manufacturing Facility Completes Post-Approval and GMP U.S. FDA Inspection Download Pdf
26 Feb Meeting conducted with Institutional Investors / Analysts Download Pdf
22 Feb Company Statement: Biocon's Insulin Manufacturing Facility in Malaysia Completes U.S. FDA (PAI) Inspection Download Pdf
19 Feb Meetings conducted with Institutional Investors / Analysts Download Pdf
18 Feb Meetings conducted with Institutional Investors / Analysts Download Pdf
12 Feb Meeting conducted with Institutional Investors / Analysts Download Pdf
10 Feb Investor Presentation Download Pdf
07 Feb Amalgamation of Biocon Research Limited ("BRL") with Biocon Biologics India Limited ("BBIL") Download Pdf
  January 2020
30 Jan Meeting conducted with Institutional Investors / Analysts Download Pdf
27 Jan Company statement: Biocon's API Manufacturing Facility Completes Pre-Approval and GMP U.S. FDA inspection Download Pdf
23 Jan Change in the name and contact details of Key Managerial Personnel under the Policy for Determination of Materiality for Disclosures Download Pdf
23 Jan Change in Directorate Download Pdf
23 Jan Biocon Q3FY20 Earnings Revenue at Rs 1,784 Cr, Up 14%; EBITDA at Rs 480 Cr, Up 18%; Net Profit (before exceptional item) at Rs 225 Cr, Up 6% Download Pdf
23 Jan Outcome of the Board Meeting Download Pdf
21 Jan Allotment of shares by BBIL to Activ Pine LLP Download Pdf
20 Jan Biocon's Oral Solid Dosage Manufacturing Facility Completes Pre-Approval U.S. FDA lnspection with Zero Observations Download Pdf
09 Jan Execution of SHA and SSA with True North - Disclosure pursuant to Regulation 30 of SEBI Regulations, 2015 Download Pdf
06 Jan Notice of Board Meeting- Newspaper Advertisement Download Pdf
06 Jan Press Release Download Pdf
06 Jan True North to Invest Rs 536.25 Crore in Biocon Biologics for 2.44% Stake Download Pdf
03 Jan Intimation of Board Meeting and Trading Window Closure Download Pdf

 
     
 January to June 2020
 January to December 2019
 January to December 2018
 January to December 2017
 January to December 2016
 December 2015
 
 
     
  Biocon

Businesses

Recommended sites Biocon on  
  Home
About Us

Investor Relations
Media Relations
Careers
Site Map
Contact Us
Our Growth Accelerators
Fact Sheet
Branded Formulations
Biopharmaceuticals
Research Services
Active Discovery Program

ABLE
Karnataka Vision Group on BT
Syngene International
Biocon Academy

    Linked In   
       
  Report adverse event/side effects and product complaints    
       
  * Disclaimer            © 2018, Biocon. All Rights Reserved